JP2012228272A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012228272A5 JP2012228272A5 JP2012187518A JP2012187518A JP2012228272A5 JP 2012228272 A5 JP2012228272 A5 JP 2012228272A5 JP 2012187518 A JP2012187518 A JP 2012187518A JP 2012187518 A JP2012187518 A JP 2012187518A JP 2012228272 A5 JP2012228272 A5 JP 2012228272A5
- Authority
- JP
- Japan
- Prior art keywords
- framework
- single chain
- chain framework
- amino acid
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 230000004927 fusion Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 238000010276 construction Methods 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 108020001775 protein parts Proteins 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 238000010200 validation analysis Methods 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38264902P | 2002-05-22 | 2002-05-22 | |
| US60/382,649 | 2002-05-22 | ||
| US43825603P | 2003-01-03 | 2003-01-03 | |
| US60/438,256 | 2003-01-03 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010060713A Division JP2010187678A (ja) | 2002-05-22 | 2010-03-17 | 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013019425A Division JP6100544B2 (ja) | 2002-05-22 | 2013-02-04 | 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012228272A JP2012228272A (ja) | 2012-11-22 |
| JP2012228272A5 true JP2012228272A5 (OSRAM) | 2013-03-21 |
| JP6075836B2 JP6075836B2 (ja) | 2017-02-08 |
Family
ID=29553590
Family Applications (10)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004506369A Withdrawn JP2006508638A (ja) | 2002-05-22 | 2003-05-21 | 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法 |
| JP2010060713A Withdrawn JP2010187678A (ja) | 2002-05-22 | 2010-03-17 | 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法 |
| JP2012187518A Expired - Lifetime JP6075836B2 (ja) | 2002-05-22 | 2012-08-28 | 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法 |
| JP2013019425A Expired - Lifetime JP6100544B2 (ja) | 2002-05-22 | 2013-02-04 | 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法 |
| JP2013193935A Pending JP2013256533A (ja) | 2002-05-22 | 2013-09-19 | 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法 |
| JP2015161601A Pending JP2015214583A (ja) | 2002-05-22 | 2015-08-19 | 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法 |
| JP2015161600A Expired - Lifetime JP6261136B2 (ja) | 2002-05-22 | 2015-08-19 | 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法 |
| JP2017161036A Pending JP2017201990A (ja) | 2002-05-22 | 2017-08-24 | 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法 |
| JP2019009288A Expired - Lifetime JP6918033B2 (ja) | 2002-05-22 | 2019-01-23 | 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法 |
| JP2020085288A Pending JP2020171286A (ja) | 2002-05-22 | 2020-05-14 | 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004506369A Withdrawn JP2006508638A (ja) | 2002-05-22 | 2003-05-21 | 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法 |
| JP2010060713A Withdrawn JP2010187678A (ja) | 2002-05-22 | 2010-03-17 | 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法 |
Family Applications After (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013019425A Expired - Lifetime JP6100544B2 (ja) | 2002-05-22 | 2013-02-04 | 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法 |
| JP2013193935A Pending JP2013256533A (ja) | 2002-05-22 | 2013-09-19 | 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法 |
| JP2015161601A Pending JP2015214583A (ja) | 2002-05-22 | 2015-08-19 | 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法 |
| JP2015161600A Expired - Lifetime JP6261136B2 (ja) | 2002-05-22 | 2015-08-19 | 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法 |
| JP2017161036A Pending JP2017201990A (ja) | 2002-05-22 | 2017-08-24 | 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法 |
| JP2019009288A Expired - Lifetime JP6918033B2 (ja) | 2002-05-22 | 2019-01-23 | 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法 |
| JP2020085288A Pending JP2020171286A (ja) | 2002-05-22 | 2020-05-14 | 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US8853362B2 (OSRAM) |
| EP (5) | EP2314622B1 (OSRAM) |
| JP (10) | JP2006508638A (OSRAM) |
| CN (4) | CN105175535A (OSRAM) |
| AU (2) | AU2003238370B2 (OSRAM) |
| CA (2) | CA2483285C (OSRAM) |
| CY (1) | CY1114225T1 (OSRAM) |
| DK (2) | DK1506236T3 (OSRAM) |
| ES (3) | ES2656427T3 (OSRAM) |
| HU (1) | HUE048922T2 (OSRAM) |
| NZ (1) | NZ536412A (OSRAM) |
| PT (2) | PT2332989E (OSRAM) |
| SI (2) | SI2332989T1 (OSRAM) |
| WO (1) | WO2003097697A2 (OSRAM) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0226727D0 (en) * | 2002-11-15 | 2002-12-24 | Medical Res Council | Intrabodies |
| EP2368992A3 (en) | 2005-03-25 | 2012-03-14 | National Research Council Of Canada | Method for isolation of soluble polypeptides |
| AU2013207650B2 (en) * | 2005-06-07 | 2016-04-21 | Esbatech, An Alcon Biomedical Research Unit Llc | Stable and soluble antibodies inhibiting TNFalpha |
| AU2016204739C1 (en) * | 2005-06-07 | 2017-10-19 | Esbatech, An Alcon Biomedical Research Unit Llc | Stable and soluble antibodies inhibiting TNFalpha |
| AU2011265593B2 (en) * | 2005-06-07 | 2013-08-15 | Esbatech, An Alcon Biomedical Research Unit Llc | Stable and soluble antibodies inhibiting TNFalpha |
| EP1891110A2 (en) | 2005-06-07 | 2008-02-27 | Esbatech AG | STABLE AND SOLUBLE ANTIBODIES INHIBITING TNF-alpha |
| AU2007246144B2 (en) | 2006-04-28 | 2012-12-06 | Delenex Therapeutics Ag | Antibodies binding to the extracellular domain of the Receptor Tyrosine Kinase ALK |
| ES2820837T3 (es) | 2006-07-10 | 2021-04-22 | Esbatech Alcon Biomed Res Unit | Anticuerpos scFv que pasan las capas epitelial y/o endotelial |
| EP3202786A3 (en) | 2007-03-12 | 2017-10-11 | ESBATech, an Alcon Biomedical Research Unit LLC | Sequence based engineering and optimization of single chain antibodies |
| WO2008131575A2 (en) * | 2007-04-27 | 2008-11-06 | Esbatech Ag | Anti-alk antibodies suitable for treating metastatic cancers or tumors |
| BRPI0813287A2 (pt) * | 2007-06-25 | 2014-12-30 | Esbatech Alcon Biomed Res Unit | Planejamento e otimização baseados na sequência de anticorpos de cadeia única |
| CA2689941C (en) * | 2007-06-25 | 2019-10-29 | Esbatech Ag | Methods of modifying antibodies, and modified antibodies with improved functional properties |
| SG188136A1 (en) | 2007-09-13 | 2013-03-28 | Delenex Therapeutics Ag | HUMANIZED ANTIBODIES AGAINST THE ß-AMYLOYD PEPTIDE |
| WO2009155723A2 (en) * | 2008-06-25 | 2009-12-30 | Esbatech, An Alcon Biomedical Research Unit Llc | STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα |
| PT2752428T (pt) * | 2008-06-25 | 2020-02-14 | Novartis Ag | Humanização de anticorpos de coelho com utilização de um framework de anticorpos universal |
| MX345395B (es) * | 2008-06-25 | 2017-01-30 | Esbatech Alcon Biomed Res Unit | Humanizacion de anticuerpos de conejos usando una estructura de anticuerpos universal. |
| AU2013202997B2 (en) * | 2008-06-25 | 2015-01-22 | Novartis Ag | STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFalpha |
| AU2016273957C1 (en) * | 2008-06-25 | 2019-04-18 | Novartis Ag | STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFa |
| MX2011000074A (es) | 2008-06-25 | 2011-02-24 | Esbatech Alcon Biomed Res Unit | Optimizacion de solubilidad de inmuno-aglutinantes. |
| AU2015201794B2 (en) * | 2008-06-25 | 2017-01-19 | Novartis Ag | STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFa |
| KR101737466B1 (ko) | 2008-06-25 | 2017-05-18 | 에스바테크 - 어 노바티스 컴파니 엘엘씨 | Ｖｅｇｆ를 억제하는 안정하고 가용성인 항체 |
| EP3964526A1 (en) | 2008-06-25 | 2022-03-09 | Novartis AG | Humanization of rabbit antibodies using a universal antibody framework |
| US8637022B2 (en) | 2008-06-30 | 2014-01-28 | Esbatech, An Alcon Biomedical Research Unit Llc | Functionalized polypeptides |
| WO2010003268A2 (en) | 2008-07-10 | 2010-01-14 | Esbatech, An Alcon Biomedical Research Unit Llc | Methods and compositions for enhanced delivery of macromolecules |
| SG10201408247SA (en) * | 2009-02-24 | 2015-02-27 | Esbatech Alcon Biomed Res Unit | Methods for identifying immunobinders of cell-surface antigens |
| CA2744103C (en) | 2009-02-24 | 2018-01-02 | Esbatech, An Alcon Biomedical Research Unit Llc | Methods for identifying immunobinders of cell-surface antigens |
| US8399624B1 (en) | 2009-06-25 | 2013-03-19 | Esbatech, An Alcon Biomedical Research Unit Llc | Acceptor framework for CDR grafting |
| US8771669B1 (en) | 2010-02-09 | 2014-07-08 | David Gordon Bermudes | Immunization and/or treatment of parasites and infectious agents by live bacteria |
| US9597379B1 (en) | 2010-02-09 | 2017-03-21 | David Gordon Bermudes | Protease inhibitor combination with therapeutic proteins including antibodies |
| US8524220B1 (en) | 2010-02-09 | 2013-09-03 | David Gordon Bermudes | Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria |
| UY33679A (es) | 2010-10-22 | 2012-03-30 | Esbatech | Anticuerpos estables y solubles |
| EP2476754A1 (en) * | 2011-01-14 | 2012-07-18 | Bundesrepublik Deutschland, Letztvertreten Durch Den Präsidenten Des Paul-Ehrlich-Instituts | Methods for the identification and repair of amino acid residues destabilizing single-chain variable fragments (scFv) |
| CN103890246A (zh) | 2011-08-18 | 2014-06-25 | 亲和生物科学公司 | 可溶性多肽 |
| AU2012325232B2 (en) | 2011-10-20 | 2017-08-31 | Esbatech - A Novartis Company Llc | Stable multiple antigen-binding antibody |
| CN106986934B (zh) * | 2012-08-22 | 2021-09-14 | 财团法人牧岩生命工学研究所 | 超稳定免疫球蛋白可变结构域的筛选和改造方法及其应用 |
| JP6333271B2 (ja) | 2012-11-05 | 2018-06-06 | セル メディカ スイッツァランド アーゲー | ＩＬ−１βへの結合メンバー |
| ES2895848T3 (es) | 2012-12-17 | 2022-02-22 | Cell Medica Inc | Anticuerpos contra IL-1 beta |
| JP2016506974A (ja) * | 2013-02-15 | 2016-03-07 | エスバテック − ア ノバルティスカンパニー エルエルシー | Ｃｄｒグラフトのためのアクセプターフレームワーク |
| RU2015139890A (ru) * | 2013-02-20 | 2017-03-27 | ИЭсБиЭйТЕК - Э НОВАРТИС КОМПАНИ ЭлЭлСи | Акцепторный каркасный участок для пересадки cdr |
| EP2981822B1 (en) | 2013-05-06 | 2020-09-02 | Scholar Rock, Inc. | Compositions and methods for growth factor modulation |
| US9737592B1 (en) | 2014-02-14 | 2017-08-22 | David Gordon Bermudes | Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment |
| US9879087B2 (en) | 2014-11-12 | 2018-01-30 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
| MX2017006167A (es) | 2014-11-12 | 2018-03-23 | Siamab Therapeutics Inc | Compuestos que interactúan con glicanos y métodos de uso. |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| JP7017015B2 (ja) | 2015-10-13 | 2022-02-08 | エウレカ セラピューティクス インコーポレイテッド | ヒトｃｄ１９に特異的な抗体剤及びその使用 |
| RU2767209C2 (ru) | 2015-10-23 | 2022-03-16 | Еурека Терапьютикс, Инк. | Химерные конструкции антитело/т-клеточный рецептор и их применения |
| CN116217729A (zh) | 2015-11-12 | 2023-06-06 | 思进公司 | 聚糖相互作用化合物及使用方法 |
| BR112018067696A2 (pt) | 2016-02-25 | 2019-01-08 | Cell Medica Switzerland Ag | membros de ligação à pd-l1 |
| IL265484B1 (en) | 2016-09-21 | 2025-09-01 | Aptevo Res & Development Llc | Cd123 binding proteins and related compositions and methods |
| US11401330B2 (en) | 2016-11-17 | 2022-08-02 | Seagen Inc. | Glycan-interacting compounds and methods of use |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| WO2018160909A1 (en) | 2017-03-03 | 2018-09-07 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
| WO2019199941A1 (en) * | 2018-04-10 | 2019-10-17 | Northwestern University | Extracellular vesicles comprising targeting affinity domain-based membrane proteins |
| WO2020069349A1 (en) * | 2018-09-27 | 2020-04-02 | Colorado State University Research Foundation | Scfv's for live cell imaging and other uses |
| US12285437B2 (en) | 2019-10-30 | 2025-04-29 | The Research Foundation For The State University Of New York | Reversing the undesirable pH-profile of doxorubicin via activation of a disubstituted maleamic acid prodrug at tumor acidity |
| AU2021308712B2 (en) | 2020-07-16 | 2025-10-09 | Novartis Ag | Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules |
| KR20230154994A (ko) | 2021-03-10 | 2023-11-09 | 마빌론 아게 | Tdp-43에 대한 항체 및 이의 용도 |
| EP4469081A1 (en) | 2022-01-24 | 2024-12-04 | Cambridge Enterprise Limited | Tau therapy |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
| US5817311A (en) * | 1993-03-05 | 1998-10-06 | Universite Catholique De Louvain | Methods of inhibiting T-cell medicated immune responses with LO-CD2a-specific antibodies |
| DE4425115A1 (de) | 1994-07-15 | 1996-01-18 | Boehringer Mannheim Gmbh | Verfahren zur Modifizierung der Stabilität von Antikörpern |
| CA2229043C (en) | 1995-08-18 | 2016-06-07 | Morphosys Gesellschaft Fur Proteinoptimierung Mbh | Protein/(poly)peptide libraries |
| US6706484B1 (en) * | 1995-08-18 | 2004-03-16 | Morphosys Ag | Protein/(poly)peptide libraries |
| US6262238B1 (en) | 1997-01-14 | 2001-07-17 | Roche Diagnostic, Gmbh | Process for modifying the stability of antibodies |
| AU3587599A (en) | 1997-11-28 | 1999-06-16 | Invitrogen Corporation | Single chain monoclonal antibody fusion reagents that regulate transcript ion in vivo |
| GB2344886B (en) | 1999-03-10 | 2000-11-01 | Medical Res Council | Selection of intracellular immunoglobulins |
| DK1242457T3 (da) * | 1999-12-28 | 2004-12-20 | Esbatech Ag | Intracellulære antistoffer [intracellulære antistoffer] med defineret struktur, der er stabil i et reducerende miljö, og anvendelse deraf |
| GB0008419D0 (en) | 2000-04-05 | 2000-05-24 | Bioinvent Int Ab | A method for invitro molecular evolution of antibody function |
| EP1156062A1 (en) | 2000-05-12 | 2001-11-21 | GPC Biotech AG | Immunomodulatory human MHC class II antigen-binding peptides/proteins |
| US6410271B1 (en) | 2000-06-23 | 2002-06-25 | Genetastix Corporation | Generation of highly diverse library of expression vectors via homologous recombination in yeast |
| DE10039191C1 (de) | 2000-08-10 | 2002-01-17 | Infineon Technologies Ag | Hochfrequenz-Eingangsstufe |
-
2003
- 2003-05-21 CN CN201510685456.0A patent/CN105175535A/zh active Pending
- 2003-05-21 CA CA2483285A patent/CA2483285C/en not_active Expired - Lifetime
- 2003-05-21 ES ES10010455.3T patent/ES2656427T3/es not_active Expired - Lifetime
- 2003-05-21 SI SI200332427T patent/SI2332989T1/sl unknown
- 2003-05-21 SI SI200332610T patent/SI2947095T1/sl unknown
- 2003-05-21 ES ES03732434T patent/ES2399617T3/es not_active Expired - Lifetime
- 2003-05-21 EP EP10010455.3A patent/EP2314622B1/en not_active Expired - Lifetime
- 2003-05-21 EP EP15160739.7A patent/EP2947095B1/en not_active Expired - Lifetime
- 2003-05-21 CN CN201410031953.4A patent/CN103739706B/zh not_active Expired - Lifetime
- 2003-05-21 PT PT100098573T patent/PT2332989E/pt unknown
- 2003-05-21 DK DK03732434.0T patent/DK1506236T3/da active
- 2003-05-21 CN CN201010575786.1A patent/CN102093477B/zh not_active Expired - Lifetime
- 2003-05-21 PT PT37324340T patent/PT1506236E/pt unknown
- 2003-05-21 US US10/515,241 patent/US8853362B2/en not_active Expired - Lifetime
- 2003-05-21 EP EP10009857.3A patent/EP2332989B1/en not_active Expired - Lifetime
- 2003-05-21 JP JP2004506369A patent/JP2006508638A/ja not_active Withdrawn
- 2003-05-21 AU AU2003238370A patent/AU2003238370B2/en not_active Expired
- 2003-05-21 EP EP03732434A patent/EP1506236B1/en not_active Expired - Lifetime
- 2003-05-21 ES ES10009857.3T patent/ES2537104T3/es not_active Expired - Lifetime
- 2003-05-21 HU HUE15160739A patent/HUE048922T2/hu unknown
- 2003-05-21 EP EP19200477.8A patent/EP3656787A1/en not_active Withdrawn
- 2003-05-21 DK DK10009857.3T patent/DK2332989T3/en active
- 2003-05-21 WO PCT/EP2003/005324 patent/WO2003097697A2/en not_active Ceased
- 2003-05-21 CN CN038146266A patent/CN1662556B/zh not_active Expired - Lifetime
- 2003-05-21 CA CA2867542A patent/CA2867542C/en not_active Expired - Lifetime
- 2003-05-21 NZ NZ536412A patent/NZ536412A/en not_active IP Right Cessation
-
2010
- 2010-03-17 JP JP2010060713A patent/JP2010187678A/ja not_active Withdrawn
- 2010-06-24 AU AU2010202634A patent/AU2010202634B2/en not_active Expired
-
2012
- 2012-08-28 JP JP2012187518A patent/JP6075836B2/ja not_active Expired - Lifetime
-
2013
- 2013-02-04 JP JP2013019425A patent/JP6100544B2/ja not_active Expired - Lifetime
- 2013-04-08 CY CY20131100292T patent/CY1114225T1/el unknown
- 2013-09-19 JP JP2013193935A patent/JP2013256533A/ja active Pending
-
2014
- 2014-08-26 US US14/469,276 patent/US9518108B2/en not_active Expired - Fee Related
-
2015
- 2015-08-19 JP JP2015161601A patent/JP2015214583A/ja active Pending
- 2015-08-19 JP JP2015161600A patent/JP6261136B2/ja not_active Expired - Lifetime
-
2016
- 2016-11-01 US US15/340,195 patent/US10125186B2/en not_active Expired - Lifetime
-
2017
- 2017-08-24 JP JP2017161036A patent/JP2017201990A/ja active Pending
-
2018
- 2018-10-30 US US16/175,002 patent/US10570190B2/en not_active Expired - Fee Related
-
2019
- 2019-01-23 JP JP2019009288A patent/JP6918033B2/ja not_active Expired - Lifetime
- 2019-12-16 US US16/716,137 patent/US20200165322A1/en not_active Abandoned
-
2020
- 2020-05-14 JP JP2020085288A patent/JP2020171286A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012228272A5 (OSRAM) | ||
| JP2014515602A5 (OSRAM) | ||
| López-Marqués et al. | Structure and mechanism of ATP-dependent phospholipid transporters | |
| Gijs et al. | Aptamers as radiopharmaceuticals for nuclear imaging and therapy | |
| EA201400811A1 (ru) | Двойная индуцированная антигеном двухкомпонентная функциональная комплементация | |
| JP2015143226A5 (OSRAM) | ||
| BRPI0813898A2 (pt) | métodos para selecionar um peptídeo ou polipeptídeo resistente à protease de um repertório de peptídeo ou polipeptídeos, para produzir um repertório de peptídeos ou polipeptídeos resistentes à protease, para fabricar um peptídeo ou polipeptídeo resistente à protease, e para tratar uma doença, peptídeo ou polipeptídeo resistente à protease, domínio variável simples de imunoglobulina resistente à protease isolada, antagonista, uso de um antagonista, ácido nucleico, vetor, e, célula hospedeira. | |
| EA202091710A1 (ru) | Антитела против cd73 и способы их применения | |
| Zhou et al. | Structural perspective on the formation of ribonucleoprotein complex in negative-sense single-stranded RNA viruses | |
| EA201691111A1 (ru) | Химерные белки фактора viii и их применение | |
| JP2010227108A5 (OSRAM) | ||
| JP2016053091A5 (OSRAM) | ||
| WO2013182910A3 (en) | Transcription activator-like effector (tale) fusion protein | |
| JP2016502843A5 (OSRAM) | ||
| JP2018138049A5 (OSRAM) | ||
| JP2016185981A5 (OSRAM) | ||
| JP2017048194A5 (OSRAM) | ||
| JP2013172734A5 (OSRAM) | ||
| FI3683235T3 (fi) | Anti-IL-33-vasta-aineita ja niiden käyttöjä | |
| JP2020501532A5 (OSRAM) | ||
| MX350962B (es) | Metodo para fabricar moleculas heterodimericas de fragmentos cristalizables de anticuerpo, utilizando efectos electrostaticos de direccion. | |
| EA201391109A1 (ru) | Молекулы нуклеиновой кислоты, кодирующие новые антигены герпеса, вакцина, включающая их, и способы их использования | |
| BR112016018598A2 (pt) | vetor de vírus adeno-associados | |
| JP2016104790A5 (OSRAM) | ||
| WO2009061413A3 (en) | Hybrid fusion reporter and uses thereof |